News and reflections from the world of AI

    Introduction to tCECs: a novel method for cancer diagnostics

    Cancer Diagnostics Expedited by the COVID-19 pandemic and the disruption it caused to healthcare systems, cancer rates are rising worldwide. Yet, ...
    Written by Aiforia

    Aiforia and X-ZELL partner to scale up novel AI-powered method for early cancer detection

    Singapore, Helsinki -- Aiforia, a leading software company providing artificial intelligence (AI) solutions for medical image analysis, and X-ZELL, a ...
    Written by Aiforia

    5 reasons to use AI in clinical diagnostics

    Rising rates of disease like cancer increase sample numbers creating a bigger burden on pathologists, an already underrepresented group of healthcare ...
    Written by Aiforia
    March 26, 2021

    Benefits of AI and digital pathology to the clinical lab: interview with pathologists Dr. Mirtti and Dr. Sandeman

    Pathologists have been examining glass slides under a microscope for over 150 years. Only recently did laboratories around the world start digitizing their slides, enabling more efficient workflows and increased accuracy in diagnostics. Adding AI to the newly digitized practice has the potential to increase these benefits exponentially. In this interview pathologists from Sweden and Finland share ...
    Written by Aiforia
    March 16, 2021

    Validation of PD-L1 AI model launches in six labs across the Netherlands

    Introduction  Programmed death-ligand 1 (PDL1) is a protein that, when attached to T cells, prevent the immune system from killing cancer cells. Hence, PDL1 is used as a biomarker for tumor immune escape, a sign of increasing cancer progression. PDL1 percentage is also a significant predictor for immunotherapy efficacy, whereby immune checkpoint inhibitors bind to PDL1 and block its ability to ...
    Written by Aiforia
    February 4, 2021

    DECIDER project launches to improve diagnostics and treatment of ovarian cancer

    The European Union has funded a project to improve personalized treatments for ovarian cancer with nearly 15 million euros for five years. The international DECIDER project has partners from 14 organizations in seven EU countries.
    Written by Aiforia
    1 2